At EuroPCR 2026, transcatheter aortic regurgitation therapy stood out as a core structural heart disease topic. Featuring real-world JenaValve cases, the first head-to-head EROCIA trial results of TAVR vs SAVR for isolated AR, and the Aortic Regurgitation in 2026 symposium, the event saw global experts exchange insights on AR diagnosis, treatment strategies, dedicated devices and evidence-based research directions.
As a leading specialized device for AR transcatheter intervention, the JenaValve Trilogy System was showcased across multiple sessions, validating its value in complex AR anatomies, clinical studies and long-term therapeutic algorithms.
